Lantheus Holdings, Inc. (NASDAQ:LNTH) is Reinhart Partners LLC.’s 2nd Largest Position

Reinhart Partners LLC. raised its holdings in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 9.9% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 1,366,873 shares of the medical equipment provider’s stock after buying an additional 123,282 shares during the period. Lantheus comprises 4.7% of Reinhart Partners LLC.’s portfolio, making the stock its 2nd largest holding. Reinhart Partners LLC.’s holdings in Lantheus were worth $122,280,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in LNTH. Signaturefd LLC raised its stake in Lantheus by 40.5% during the third quarter. Signaturefd LLC now owns 319 shares of the medical equipment provider’s stock valued at $35,000 after purchasing an additional 92 shares in the last quarter. UMB Bank n.a. raised its stake in shares of Lantheus by 42.1% in the third quarter. UMB Bank n.a. now owns 425 shares of the medical equipment provider’s stock valued at $47,000 after acquiring an additional 126 shares during the period. GAMMA Investing LLC raised its stake in shares of Lantheus by 45.5% in the third quarter. GAMMA Investing LLC now owns 467 shares of the medical equipment provider’s stock valued at $51,000 after acquiring an additional 146 shares during the period. Wilmington Savings Fund Society FSB bought a new stake in shares of Lantheus in the 3rd quarter worth about $25,000. Finally, CWM LLC lifted its holdings in shares of Lantheus by 63.0% in the 3rd quarter. CWM LLC now owns 750 shares of the medical equipment provider’s stock worth $82,000 after acquiring an additional 290 shares during the last quarter. 99.06% of the stock is owned by hedge funds and other institutional investors.

Lantheus Trading Down 1.7 %

NASDAQ LNTH traded down $1.61 on Monday, hitting $94.27. 574,718 shares of the company’s stock traded hands, compared to its average volume of 794,424. Lantheus Holdings, Inc. has a 1-year low of $50.20 and a 1-year high of $126.89. The firm’s 50-day moving average price is $90.39 and its two-hundred day moving average price is $99.69. The firm has a market capitalization of $6.55 billion, a PE ratio of 15.69 and a beta of 0.46.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on the stock. StockNews.com lowered shares of Lantheus from a “buy” rating to a “hold” rating in a report on Thursday, November 21st. JMP Securities decreased their price objective on shares of Lantheus from $125.00 to $112.00 and set a “market outperform” rating for the company in a report on Thursday, November 7th. The Goldman Sachs Group started coverage on shares of Lantheus in a report on Wednesday, December 18th. They set a “buy” rating and a $143.00 price objective for the company. Finally, Truist Financial reiterated a “buy” rating and set a $120.00 price objective (down previously from $135.00) on shares of Lantheus in a report on Friday, November 8th. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $131.86.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.